Vivian Jean M. Cline-Burkhardt

A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer

Antonio Jimeno, Keisuke Shirai, Minsig Choi et al. · Annals of Oncology · 2014 · 99 citations · Full text

Medicine, Oncology, Pharmacology +12

A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma

Daniel W. Bowles, Mark D. Kochenderfer, Allen Lee Cohn et al. · Clinical Colorectal Cancer · 2016 · 42 citations

Medicine, Oncology, Pharmacology +15

SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) <i>KRAS</i> metastatic colorectal cancer (mCRC).

J. Randolph Hecht, Allen Lee Cohn, Shaker R. Dakhil et al. · Journal of Clinical Oncology · 2013 · 21 citations

Medicine, Oncology, Pharmacology +14

SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) <i>KRAS</i> metastatic colorectal cancer (mCRC).

Allen Lee Cohn, J. Randolph Hecht, Shaker R. Dakhil et al. · Journal of Clinical Oncology · 2013 · 20 citations

Medicine, Oncology, Pharmacology +14

Brentuximab Vedotin in Combination with Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study

Christopher A. Yasenchak, Andres Forero‐Torres, Vivian Jean M. Cline-Burkhardt et al. · Blood · 2015 · 15 citations

Medicine, Oncology, Pharmacotherapy +12